Serological responses to killed oral cholera vaccine (OCV) when given 4 years after initial receipt of OCV in Cameroon: A randomized controlled trial

在喀麦隆,首次接种灭活口服霍乱疫苗 (OCV) 4 年后再次接种 OCV 的血清学反应:一项随机对照试验

阅读:1

Abstract

Oral cholera vaccination (OCV) is one of strategies to help control cholera with two doses recommended as initial vaccination and booster doses recommended 3-5 years later to prevent future outbreaks. There is no actual recommendation on the number of doses required during booster vaccination. An OCV campaign conducted in Mogode-Cameroon provided an opportunity to determine if revaccination four years after would induce a booster response. 350 people living in Mogode-Cameroon, who received 0, 1 or 2 doses of OCV four years earlier, were stratified into age groups, < 5, 5-14, and >14 and randomized into two arms. Arm A received a single dose and Arm B received two doses 14 days apart. We aimed to determine if people who had received OCV four years earlier responded with a booster immune response compared to those not vaccinated. Serum samples were collected at baseline and at multiple time points after vaccination to measure vibriocidal antibody titers. For Arm A, vibriocidal GMT significantly increased nine days after the first dose with a response rate of 61-70%; however, early vibriocidal response (day 4-6) was rare (22%) and were similar in those who had received vaccine four years earlier and those who did not. Ogawa, but not Inaba, vibriocidal responses were higher on day 9 for those who had been vaccinated earlier, but vibriocidal titers during subsequent timepoints were similar in all study arms. In Arm B, there were no early response (day 4-6) after the second dose. Overall, OCV induced a measurable immune response by day 9, but no evidence of a rapid booster response was detected following revaccination. Since there was no evidence that the earlier vaccination stimulated a booster response when vaccination is repeated, this suggests that persons being revaccinated should receive the two doses as was recommended initially. Trial registration: Pan African Clinical Trials Registry under the reference PACTR202102660004195.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。